Skip to main content
Clinical Trials/EUCTR2011-005495-42-DK
EUCTR2011-005495-42-DK
Active, not recruiting
Not Applicable

Individualised first line chemotherapy in metastatic colo-rectal cancer (mCRC).Is plasma TIMP-1 a predictive factor for best choise of first line chemotherapy in mCRC? - Individualised choise of 1.line chemotherapy in metastatic colo-rectal cancer

Kell Osterlind0 sites210 target enrollmentApril 18, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metastatic colon or rectal cancer
Sponsor
Kell Osterlind
Enrollment
210
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 18, 2012
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Kell Osterlind

Eligibility Criteria

Inclusion Criteria

  • Histologically proven colon or rectal cancer
  • Metastatic disease primary (stage IV) or due to relapse of previous (resected) stage I\-III disease
  • At least 1 measurable lesion
  • 18 years of age or older
  • WHO performance status \<3
  • Expected survival \>3 months
  • Hgb\>6\.1 mmol/L, WBC\>2\.9, platelets\>99
  • Kidney and liver function tests below certain defined upper limits
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • Previous chemotherapy (including adjuvant after primary surgery)
  • Previous cancer (except non melanoma skin cancer)
  • Allergy to any of the therapeutical substances
  • Neuropathy (e.g. alcoholic or diabetic)
  • Recent myocardial infarction or stroke
  • Uncontrollable hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumabmetastatic colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2009-013099-38-DEKlinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand450
Not yet recruiting
Phase 3
A study to see effectiveness of chemotherapy for older patients with lung cancer.Health Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecified
CTRI/2022/07/044193Tata Memorial Hospital
Active, not recruiting
Not Applicable
Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®)metastasiertes MammakarzinomMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancer
EUCTR2005-004234-41-DEOtto-von-Guericke Universität Magdeburg
Active, not recruiting
Not Applicable
Individual Therapy by Gene Expression for Colon Cancer Patients
EUCTR2012-001307-20-ESFundación Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO)
Active, not recruiting
Not Applicable
Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL - PTCL intensive chemo-immunotherapyon Hodgkin peripheral T-cell lymphomasMedDRA version: 6.1Level: PTClassification code 10034623
EUCTR2006-004234-33-ITISTITUTO NAZIONALE PER LA CURA TUMORI111